First clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the US

Trial Profile

First clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the US

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Nanobiotix
  • Most Recent Events

    • 03 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top